Orphalan Overview
- Year Founded
-
2011
- Status
-
Private
- Employees
-
137
- Latest Deal Type
-
2ndary - Private
- Investors
-
2
Orphalan General Information
Description
Developer of treatments for rare diseases intended to improve the lives of patients. The company uses a global network of experts, including scientists, academic institutions, and companies, to identify, develop, and provide access to treatments for patients with rare diseases to make a positive difference, enabling healthcare workers to provide treatments and services that work for patients.
Contact Information
Website
www.orphalan.comCorporate Office
- 226 Boulevard Voltaire
- 75011 Paris
- France
Corporate Office
- 226 Boulevard Voltaire
- 75011 Paris
- France
Orphalan Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Secondary Transaction - Private | 01-Dec-2024 | Completed | Generating Revenue | |||
| 3. Debt - General | 02-Jan-2019 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 01-Jan-2015 | Completed | Generating Revenue | |||
| 1. Accelerator/Incubator | 01-Jan-2011 | Completed | Startup |
Orphalan Patents
Orphalan Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260130867-A1 | Formulation | Pending | 08-Nov-2024 | ||
| EP-4777083-A1 | Formulation comprising triethylenetetramine tetrahydrochloride | Pending | 08-Nov-2024 | ||
| ES-3082744-T1 | Formulation comprising triethylenetetramine tetrahydrochloride | Pending | 08-Nov-2024 | ||
| WO-2026099431-A1 | Formulation comprising triethylenetetramine tetrahydrochloride | Pending | 08-Nov-2024 | ||
| EP-4329738-A1 | Non-ceruloplasmin bound copper level monitoring | Pending | 26-Apr-2021 | A61K31/132 |
Orphalan Signals
Orphalan Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Advent Life Sciences | Venture Capital | Minority | ||
| La Synapse | Accelerator/Incubator |
Orphalan Acquisitions (1)
Orphalan’s most recent deal was a Merger/Acquisition with Orphelia Pharma.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Orphelia Pharma | Merger/Acquisition | Pharmaceuticals |
Orphalan Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Orphelia Pharma | Paris, France | 2007 |
Orphalan FAQs
-
When was Orphalan founded?
Orphalan was founded in 2011.
-
Where is Orphalan headquartered?
Orphalan is headquartered in Paris, France.
-
What is the size of Orphalan?
Orphalan has 137 total employees.
-
What industry is Orphalan in?
Orphalan’s primary industry is Biotechnology.
-
Is Orphalan a private or public company?
Orphalan is a Private company.
-
What is Orphalan’s current revenue?
The current revenue for Orphalan is .
-
Who are Orphalan’s investors?
Advent Life Sciences and La Synapse have invested in Orphalan.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process